ALT

NASDAQ 已收盘

Altimmune

1.41 USD
▲+0.02+1.44%
盘后 1.42 +0.71%
2026-11-19
市值
$258.80M
市盈率
—
EPS
-0.67
股息率
—
52 周区间
1.38 – 6.44
成交量
4.30M
Beta
0.15
目标价
16.33
52W 低 1.3852W 高 6.44
价格走势

公司简介

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.